- Home
- CTXR
as 12-18-2024 10:35am EST
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CRANFORD |
| Market Cap: | 84.9M | IPO Year: | N/A |
| Target Price: | $100.00 | AVG Volume (30 days): | 561.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.44 - $26.75 | Next Earning Date: | 02-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Citius Pharmaceuticals Inc. News
CTXR Breaking Stock News: Dive into CTXR Ticker-Specific Updates for Smart Investing
PR Newswire
23 days ago
Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval
MT Newswires
a month ago
Citius Pharmaceuticals Launching 1-for-25 Reverse Stock Split
PR Newswire
a month ago
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split
PR Newswire
a month ago
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering
MT Newswires
a month ago
Citius Pharmaceuticals to Raise $3 Million via Offering; Shares Drop
PR Newswire
a month ago
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering
MT Newswires
a month ago
Citius Shares Jump After Reporting Positive Results From Early Study of Potential Cancer Treatment
PR Newswire
a month ago
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Compare CTXR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTXR Citius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.